Business Wire

BEONTAG

17.1.2023 12:01:56 CET | Business Wire | Press release

Share
Global Label Manufacturing and Technology Company, Beontag, Secures Loan of €120 Million from Syndicate led by Deutsche Bank

Today, Beontag – one of the world’s largest manufacturers of self-adhesives and smart tags (such as digital labels, and labeling technology solutions like RFID and NFC) – announced that Tags Lux Sarl., a wholly owned subsidiary of the Company, has secured and closed a binding agreement for a syndicated loan of €120 million with global banks and Deutsche Bank as sole lead arranger.

Beontag, the second largest provider of digital RFID and NFC solutions for some of the world’s biggest fashion and consumer brands, is expected to achieve €550 Million in revenue for 2022, with international and national acquisitions, integrations and expansion contributing to significant top-line growth from pro forma actualized revenues of more than €400 Million in 2021. This is the first significant, international capital raise by the Brazilian-founded company – with operations now spanning more than 15 international facilities and a presence in over 40 countries.

Terms of Syndicated Facility

  • The syndicated loan shall mature within 60 months from closing date with 18 months grace period, including a possibility of prepayment from the 18th month.
  • Beontag intends to use the net proceeds from the issuance to primarily refinance its existing debt throughout the group. Any excess proceeds will be used to support organic strategic initiatives across multiple geographies and enhance liquidity.
  • The transaction is expected to be leverage-neutral after closing.
  • The loan shall carry an interest rate of EURIBOR plus 4.5% per annum and contains incentivised terms that are linked to Beontag 2030 ESG strategy, which is aligned to the United Nations Sustainable Development Goals (SDGs). Every year, Beontag will seek third-party verification to certify and report upon progress against the ESG-related terms agreed.

Global Expansion, Borderless Solutions

Beontag’s Chief Financial Officer, Pedro Christ, commented: “Investment is a key aspect of our journey to become a truly borderless, end-to-end solutions provider of self-adhesive label stock and IoT solutions. And we believe this syndicated capital raise is a good example of the confidence of international investors in Beontag’s global strategy, as well as our current operational fundamentals.

For 2023, and beyond, we are excited to continue to innovate and expand our solutions to meet our clients’ demands for future-focused support, all while taking care to improve our ESG credentials and reduce the impact of our sector on the planet.”

The Managing Director of Global Emerging Markets from Deutsche Bank, Ricardo Cunha, added: “We are delighted to partner with Beontag for this transaction. This commitment, with and added ESG incentive, reflects our confidence in both the strength and sustainable intention of their innovative plans for the sector.

We look forward to keep supporting Beontag as the company expands into different markets and geographies.”

ENDS

ABOUT BEONTAG

For more than 40 years, Beontag has been dedicated to developing the future of pressure sensitive label stock and RFID technology, being world leaders in both segments. Today the company’s dedicated team, leading technology, global reach, and capabilities help the world work more efficiently, reliably, and safely. Beontag´s people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill Beontag´s mission to be a digital enabler.

With modern manufacturing facilities, permanent investment and a highly qualified team, the company has been expanding its business globally and is one of the largest and most respected self-adhesive companies in Latin America. It also operates in the technology sector and has a wide portfolio of Internet of Things (IoT) solutions, focused on the manufacture of radiofrequency smart labels, as well as on the development of software for the integration of the logistics chain, traceability, and product authentication.

To learn more, visit: https://beontag.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005275/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye